NCT01946204 2026-04-13SPARTANAragon Pharmaceuticals, Inc.Phase 3 Active not recruiting1,207 enrolled 15 charts 2 FDA
NCT02465060 2026-04-13Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting6,452 enrolled 2 FDA
NCT02489318 2026-04-13TITANAragon Pharmaceuticals, Inc.Phase 3 Active not recruiting1,052 enrolled 13 charts 2 FDA